<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01008085</url>
  </required_header>
  <id_info>
    <org_study_id>ST2009-02</org_study_id>
    <nct_id>NCT01008085</nct_id>
  </id_info>
  <brief_title>STENTYS Self-expanding Versus Balloon-expandable Stent in Acute Myocardial Infarction (AMI)</brief_title>
  <acronym>APPOSITION ll</acronym>
  <official_title>Randomized Comparison Between the STENTYS Self-expanding Coronary Stent and a Balloon-expandable Stent in Acute Myocardial Infarction - APPOSITION II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stentys</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stentys</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study hypothesis: the Stentys self-expandable Stent results into a better alignment of the&#xD;
      struts to the vessel wall than a balloon-expandable stent within a few days after the&#xD;
      procedure in acute myocardial infarction patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stent strut malapposition and stent underexpansion are a common phenomenon in AMI as a result&#xD;
      of the changing anatomy after an AMI has occurred (thrombus dissolution, resolution of spasm)&#xD;
      with the traditional balloon-expandable stent treatment. A self-expanding stent might lead to&#xD;
      better stent strut apposition as it follows the contours of the vessel wall due to its&#xD;
      self-expanding properties. This might result into better long term clinical outcomes like&#xD;
      lower thrombosis rates.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stent strut apposition measured by optical coherence tomography (OCT)</measure>
    <time_frame>3 days after procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>30 days and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>Self-expanding stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stentys stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Balloon-expandable stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VISION/Driver</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stentys coronary stent</intervention_name>
    <description>Self-expanding Nitinol stent</description>
    <arm_group_label>Self-expanding stent</arm_group_label>
    <other_name>Self-expanding stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Balloon-expandable stent</intervention_name>
    <description>VISION/Driver</description>
    <arm_group_label>Balloon-expandable stent</arm_group_label>
    <other_name>VISION/Driver</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject 18 years old.&#xD;
&#xD;
          2. Acute Myocardial Infarction defined as presence of at least two of the three items&#xD;
             below:&#xD;
&#xD;
               1. Detection of rise of cardiac biomarkers with a least one value above the 99th&#xD;
                  percentile of the upper reference limit (URL)&#xD;
&#xD;
               2. Symptoms of ischaemia (chest pain) &gt;20 minutes&#xD;
&#xD;
               3. ECG changes indicative of new ischaemia: new ST-T changes (ST deviation ≥0.2mV&#xD;
                  precordial leads and/or ≥0.1mV limb leads) or new LBBB)&#xD;
&#xD;
          3. Reperfusion expected to be achieved within 12 hours from the onset of symptoms&#xD;
&#xD;
          4. Subject understands the nature of the procedure and provides written informed consent&#xD;
             prior to the catheterization procedure.&#xD;
&#xD;
          5. Subject is willing to comply with specified follow-up evaluation and can be contacted&#xD;
             by telephone.&#xD;
&#xD;
          6. Acceptable candidate for coronary artery bypass graft (CABG) surgery.&#xD;
&#xD;
          7. Male or non-pregnant female subject.&#xD;
&#xD;
        Angiographic Inclusion Criteria:&#xD;
&#xD;
          1. Reference vessel diameter &gt;2.5mm and &lt;4.0mm by visual estimate.&#xD;
&#xD;
          2. Target lesion &lt;30mm in length by visual estimate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently enrolled in another investigational device or drug study that has not&#xD;
             completed the primary endpoint or that clinically interferes with the current study&#xD;
             endpoints.&#xD;
&#xD;
          2. Coronary or cardiac intervention or major surgery of any kind within 30 days prior to&#xD;
             the procedure.&#xD;
&#xD;
          3. Target vessel supplied by by-pass vessel&#xD;
&#xD;
          4. Patients on anticoagulation therapy (Coumadin)&#xD;
&#xD;
          5. Patient received thrombolytic therapy.&#xD;
&#xD;
          6. Myocardial infarction due to stent thrombosis, or infarct lesion at the side of a&#xD;
             previously implanted stent&#xD;
&#xD;
          7. Cardiogenic shock&#xD;
&#xD;
          8. Any previous stent placement within 10mm (proximal or distal) of the target lesion.&#xD;
&#xD;
          9. Co-morbid condition(s) that could limit the subject's ability to participate in the&#xD;
             study or to comply with follow-up requirements, or impact the scientific integrity of&#xD;
             the study.&#xD;
&#xD;
         10. Concurrent medical condition with a life expectancy of less than 6 months.&#xD;
&#xD;
         11. Left ventricular ejection fraction (LVEF) &lt;30% at the most recent evaluation.&#xD;
&#xD;
         12. Cerebrovascular accident or transient ischemic attack in the last 6 months.&#xD;
&#xD;
         13. Known hypersensitivity or contraindication to aspirin, heparin or bivalirudin,&#xD;
             clopidogrel or ticlopidine, cobalt, nickel, or sensitivity to contrast media, which&#xD;
             cannot be adequately pre-medicated.&#xD;
&#xD;
         14. Known serum creatinine level &gt;2.5mg/dl or presence or history of renal failure&#xD;
&#xD;
        Angiographic Exclusion Criteria:&#xD;
&#xD;
          1. Unprotected left main coronary artery disease (obstruction greater than 50% in the&#xD;
             left main coronary artery that is not protected by at least one non-obstructed bypass&#xD;
             graft to the left anterior descending (LAD) or left circumflex (LCX) artery or a&#xD;
             branch thereof).&#xD;
&#xD;
          2. Target vessel is excessively tortuous (two bends &gt;90˚ to reach the target lesion).&#xD;
&#xD;
          3. Lesion location that is aorto-ostial or within 5mm of the origin of the LAD or LCX.&#xD;
&#xD;
          4. Target lesion is severely calcified.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Verheye, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>ZNA, Middelheim, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>C. Spaulding</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>November 4, 2009</study_first_submitted>
  <study_first_submitted_qc>November 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2009</study_first_posted>
  <last_update_submitted>January 21, 2011</last_update_submitted>
  <last_update_submitted_qc>January 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Rene Spaargaren, Chief Medical Officer</name_title>
    <organization>STENTYS</organization>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>self-expandable</keyword>
  <keyword>balloon-expandable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

